SEC Form 4Coverage since Jul 1, 2026
$NTLA insider trading
Over the last 12 months, Intellia Therapeutics insiders reported no purchases and 3 sales totaling $220K across SEC Form 4 filings. 33% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $220K 3 events
- Events · 12m
- 3 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 33% pre-arranged plans
Side
Price · $NTLA · 12Mvia TradingView
Top insiders · 12m
Dulac Edward J IIIEVP, Chief Financial Officer2× · $175K
Dube Michael PVP, Chief Accounting Officer1× · $44K
All insider trades
3 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 22, 2026 | Dulac Edward J IIIEVP, Chief Financial Officer · O | ▼ Sale | 8,111 | $11.25 | $91K | -5.2% | — |
| Jul 2, 2026 | Dulac Edward J IIIEVP, Chief Financial Officer · O | ▼ Sale | 4,677 | $18 | $84K | -2.9% | plan |
| Jul 1, 2026 | Dube Michael PVP, Chief Accounting Officer · O | ▼ Sale | 2,641 | $16.78 | $44K | -3.8% | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $NTLA feed.